Clinical trials: Moderate Psoriasis
Psoriasis
Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis
This study assessed the safety and pharmacokinetics (PK) of a single dose application of ARQ-151 cream 0.5% to 25 cm^2 of psoriatic plaque(s) (Cohort 1).
- Trial name
- NCT03392168
- Testing
- ARQ-151 cream 0.5%, ARQ-151 cream 0.15%, ARQ-151 vehicle cream
- Where
- 8 sites in United States, Canada
- Volunteers
- 91 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Psoriasis
Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.
This study was designed to prove and quantify the hypothesis that secukinumab is effective, safe and well tolerated in the treatment of moderate to severe chronic plaque-type psoriasis in patients who are inadequate responders to…
- Trial name
- SIGNATURE (NCT01961609)
- Testing
- Secukinumab (AIN457)
- Where
- 54 sites in Ireland, United Kingdom
- Volunteers
- 235 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis
The purpose of this study is to establish proof of efficacy for namilumab in moderate to severe plaque psoriasis, measured as Psoriasis Area and Severity Index (PASI)75 response rate at Week 12.
- Trial name
- NCT02129777
- Testing
- Namilumab
- Where
- 10 sites in Canada
- Volunteers
- 122 people
- Sponsor
- Takeda
Psoriasis Vulgaris
This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream
This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating the efficacy, safety and convenience of the MC2-01 cream.
- Trial name
- NCT03802344
- Testing
- MC2-01 cream, Cal/BDP combination, Vehicle
- Where
- 2 sites in Czechia, Germany
- Volunteers
- 498 people
- Sponsor
- MC2 Therapeutics
Moderate to Severe Plaque Psoriasis
Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities
This multicenter, post marketing observational study (PMOS) was designed to evaluate the effectiveness of adalimumab over a period of 9 months as determined by the Psoriasis Area and Severity Index (PASI) in participants with…
- Trial name
- EPIC (NCT01401452)
- Volunteers
- 246 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis
This was a randomized, double blind, placebo controlled, parallel group study in 129 subjects with moderate to severe psoriasis with a PASI score of at least 10.
- Trial name
- NCT02618616
- Testing
- ZPL-3893787
- Where
- 24 sites in Belgium, Germany and 2 more
- Volunteers
- 129 people
- Sponsor
- Ziarco Pharma Ltd
Psoriasis
A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy
The purpose of this study is to compare the efficacy and safety of subcutaneous (SC) risankizumab and oral FUMADERM provided as study medication in participants with moderate to severe plaque psoriasis who are naïve to and…
- Trial name
- NCT03255382
- Testing
- Fumaderm, risankizumab
- Where
- 23 sites in Germany
- Volunteers
- 120 people
- Sponsor
- AbbVie
Psoriasis Vulgaris
A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream
This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating efficacy, safety and convenience of the MC2-01 cream.
- Trial name
- NCT03308799
- Testing
- MC2-01 cream, Cal/BDP combination, Cream vehicle
- Where
- 3 sites in United States
- Volunteers
- 794 people
- Sponsor
- MC2 Therapeutics
Psoriasis
Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis
This study evaluates the treatment of psoriasis with aminopterin. Participants will be treated for 14 weeks with either aminopterin or placebo followed.
- Trial name
- NCT03431974
- Testing
- LD-Aminopterin oral capsule
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Syntrix Biosystems, Inc.
Hidradenitis Suppurativa (HS)
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
A study to evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- PIONEER I (NCT01468207)
- Testing
- adalimumab
- Volunteers
- 307 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects
The purpose of this study is to assess the safety and efficacy of brodalumab taken every two weeks at two different doses.
- Trial name
- AMAGINE-1 (NCT01708590)
- Testing
- 210 mg brodalumab, 140 mg brodalumab
- Where
- 78 sites in United States, Canada and 4 more
- Volunteers
- 661 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
The objectives of this study are to compare the safety of DFD01 Spray to Comp01 Lotion for topical treatment of moderate plaque psoriasis and to compare the efficacy of DFD01 Spray to Placebo Spray for topical treatment of…
- Trial name
- NCT01947491
- Testing
- DFD01 Spray, Comp01 Lotion, Vehicle Lotion
- Where
- 40 sites in United States
- Volunteers
- 394 people
- Sponsor
- Primus Pharmaceuticals
Psoriasis, Plaque Psoriasis
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
This Phase IIa study is designed to assess the safety, tolerability and pharmacokinetics of oral MP1032 in patients with moderate to severe psoriasis over a period of 6 weeks.
- Trial name
- NCT02908347
- Testing
- MP1032
- Where
- 4 sites in Germany
- Volunteers
- 46 people
- Sponsor
- MetrioPharm AG
Chronic Plaque Psoriasis
Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis
The purpose of this study is to determine whether PF-06700841 is safe and effective in the treatment of chronic plaque psoriasis.
- Trial name
- NCT02969018
- Testing
- PF-06700841
- Where
- 44 sites in United States, Canada and 1 more
- Volunteers
- 212 people
- Sponsor
- Pfizer
Palmoplantar Pustulosis (PPP)
A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis
The primary objective is to provide dose-ranging data for 4 dose regimens of BI 655130 compared to placebo on the primary endpoint of percentage change from baseline in PPP ASI at Week 16.
- Trial name
- NCT04015518
- Testing
- Spesolimab
- Where
- 88 sites in United States, Australia and 13 more
- Volunteers
- 152 people
- Sponsor
- Boehringer Ingelheim
Psoriasis
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Study to evaluate efficacy and safety in subjects with moderate to severe Psoriasis treated with BMS-986165
- Trial name
- NCT02931838
- Testing
- BMS-986165
- Where
- 76 sites in United States, Australia and 6 more
- Volunteers
- 268 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
This study will evaluate the efficacy of etanercept in patients with plaque psoriasis who have lost a satisfactory response to adalimumab.
- Trial name
- NCT01543204
- Testing
- Etanercept
- Where
- 47 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Amgen
Psoriasis, Skin Diseases
Study to Assess the Efficacy and Safety of Orismilast in Psoriasis
This study investigates 3 different doses of orismilast modified release compared to placebo in adult patients with moderate-to-severe plaque-type psoriasis.
- Trial name
- IASOS (NCT05190419)
- Testing
- Orismilast modified release tablets
- Where
- 34 sites in United States, Germany and 2 more
- Volunteers
- 202 people
- Sponsor
- UNION therapeutics
Plaque Psoriasis
Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis
The purpose of this study is to assess clinical response and patient satisfaction when DFD-01 is used topically twice a day for moderate plaque psoriasis.
- Trial name
- NCT02749799
- Testing
- DFD-01 (betamethasone dipropionate) Spray, 0.05%
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- Primus Pharmaceuticals
Psoriasis
Rimegepant in Moderate Plaque-type Psoriasis
The purpose of this study is to examine the use of a new investigational medication for the treatment of moderate plaque-type psoriasis.
- Trial name
- NCT04629950
- Testing
- Rimegepant
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Weill Medical College of Cornell University